Hyperfine, Inc. SEC Filings

Hyperfine, Inc. director and 10% owner Jonathan M. Rothberg received a grant of stock options covering 157,700 shares of Class A common stock. The options have an exercise price of $1.49 per share and expire on May 22, 2036.

The grant was awarded at no cost to Rothberg and is categorized as a compensation-related acquisition, not an open‑market purchase. According to the filing, all 157,700 options are held directly, and the underlying shares vest on the date of Hyperfine’s next regular annual stockholders meeting, subject to his continued service.

Hyperfine, Inc. reported the results of its 2026 annual stockholder meeting. Holders of 44,587,577 Class A shares and 15,055,288 Class B shares were present in person or by proxy, representing approximately 89.89% of the voting power, which constituted a quorum. Stockholders had one vote per Class A share and 20 votes per Class B share as of the March 25, 2026 record date.

All five nominated directors—Daniel J. Wolterman, Maria Sainz, John Dahldorf, Ruth Fattori, and Jonathan M. Rothberg, Ph.D.—were reelected to serve until the 2027 annual meeting, each receiving over 314 million votes in favor and around 1 million or fewer votes against, with broker non-votes of 29,991,466 for each nominee. Stockholders also ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 341,824,976 votes for, 3,658,781 against, and 209,580 abstentions.

Hyperfine, Inc. filed a shelf registration prospectus to register for resale up to 1,083,335 shares of Class A common stock issuable upon exercise of warrants issued in connection with a March 18, 2026 loan agreement with Horizon Technology Finance Corporation. The resale is by the Selling Securityholders; the company will not receive proceeds from resale transactions, but would receive cash only if the Warrants are exercised for cash.

The registered shares consist of Initial Warrants for 562,500 shares and Additional Warrants for 520,835 shares, each exercisable at $1.20 per share. The prospectus states potential cash proceeds of up to approximately $1.3 million if all Warrants are exercised for cash. The company bases pre-offering ownership on 84,215,048 shares outstanding as of May 1, 2026.

Hyperfine, Inc. reported strong top-line growth but continued losses for the three months ended March 31, 2026. Revenue rose to $3.9 million from $2.1 million, driven mainly by higher Swoop portable MRI device sales and a higher average selling price. Gross profit more than doubled to $2.0 million, while operating expenses fell to $10.5 million, narrowing the net loss to $8.6 million from $9.4 million.

Cash, cash equivalents and restricted cash were $41.3 million at quarter end, helped by a new $15 million draw under a senior secured term loan facility that can provide up to $40 million in total. Operating activities used $9.0 million of cash. Management believes current capital, including this financing, will fund operations for at least twelve months, but ongoing losses and limited revenue mean the business still depends on future capital raises. The company continued to secure important regulatory milestones for its AI-powered Swoop system in the United States, Europe, the United Kingdom and India, supporting its strategy to expand portable MRI adoption globally.

Hyperfine, Inc. reported strong first quarter 2026 growth while remaining unprofitable. Revenue reached $3.90 million, up 83% from $2.14 million a year earlier, driven by sales of 10 Swoop® systems versus six in the prior-year quarter. Gross profit rose to $1.98 million, and gross margin improved to 51% from 41%.

Operating expenses declined slightly, with research and development down to $3.85 million from $5.04 million. Net loss narrowed to $8.62 million, or $0.09 per share, from $9.42 million, or $0.12 per share. Cash, cash equivalents and restricted cash increased to $41.28 million, supported by a $15.0 million debt financing that extends the expected cash runway into 2028. Management reaffirmed 2026 guidance for revenue of about $20–$22 million and cash burn of $26–$28 million.

Hyperfine, Inc. calls a virtual-only 2026 annual stockholder meeting on May 21, 2026 at 10:00 a.m. Eastern Time. Stockholders of record as of March 25, 2026 may vote Class A and high‑vote Class B shares via www.virtualshareholdermeeting.com/HYPR2026 using a 16‑digit control number.

Stockholders will elect five directors and vote on ratifying Grant Thornton LLP as independent auditor for the year ending December 31, 2026. Founder Jonathan Rothberg beneficially owns all 15,055,288 Class B shares, giving him majority voting control, so the company qualifies as a Nasdaq “controlled company.”

The proxy describes Hyperfine’s AI‑powered, portable Swoop MRI platform, recent FDA, CE Mark, UKCA and India regulatory clearances, and international expansion efforts. It also details executive and director compensation, equity plans, board committees, and an executive severance plan aligned with change‑in‑control situations.

HALE BRETT reported acquisition or exercise transactions in this Form 4 filing.

Hyperfine, Inc. reported that its CFO and CAO, Brett Hale, received an equity compensation grant of 330,000 restricted stock units (RSUs) of Class A common stock. The RSUs have no cash purchase price and represent the right to receive one share per unit upon vesting.

The award vests 25% on March 23, 2027, with the remaining RSUs vesting in equal quarterly installments over the following three years, subject to his continued service. After this grant, Hale beneficially owns 605,812 shares of Class A common stock, including these RSUs.